Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A9 | P48067 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ALB | P02768 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | TACR1 | P25103 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2779265 | 1.00 | SLC6A9 (0.45) | SLC6A9HSD17B10ALBPOLBMAPK1 | |
| SCHEMBL15780321 | 1.00 | SLC6A9 (0.45) | SLC6A9HSD17B10ALBPOLBMAPK1 | |
| SCHEMBL25137537 | 0.92 | SLC6A9 (0.40) | SLC6A9HSD17B10ALBPOLBMAPK1 | |
| SCHEMBL16922658 | 0.92 | MAPT (0.44) | SLC6A9HSD17B10TACR1MAPTALDH1A1 | |
| SCHEMBL17190336 | 0.92 | MAPT (0.44) | SLC6A9HSD17B10TACR1MAPTALDH1A1 | |
| SCHEMBL15444498 | 0.89 | SLC6A9 (0.38) | SLC6A9HSD17B10ALBPOLBMAPK1 | |
| SCHEMBL12768265 | 0.89 | CHRM5 (0.40) | SLC6A9HSD17B10ALBPOLBMAPK1 | |
| SCHEMBL8562008 | 0.88 | HSD17B10 (0.43) | HSD17B10POLBMAPK1L3MBTL1MAPT | |
| SCHEMBL11713448 | 0.88 | HSD17B10 (0.43) | HSD17B10POLBMAPK1L3MBTL1MAPT | |
| SCHEMBL17706711 | 0.88 | HSD17B10 (0.43) | HSD17B10POLBMAPK1L3MBTL1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230120220-A1 | PROCESS FOR SITE-SPECIFIC MODIFICATION OF AN ANTIBODY | Orano Mining (FR) | 2023-04-20 | — | — | US | disclosed |
| US-20220184217-A1 | HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2022-06-16 | — | — | US | disclosed |
| WO-2021202830-A2 | HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2021-10-07 | — | — | WO | disclosed |
| US-20210145971-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | Fusion Pharmaceuticals Inc. (CA) | 2021-05-20 | — | — | US | disclosed |
| US-10874753-B2 | Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells | THE SOUTH AFRICAN NUCLEAR ENERGY CORPORATION LIMITED (ZA) | 2020-12-29 | — | — | US | disclosed |
| WO-2020205948-A1 | HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2020-10-08 | — | — | WO | disclosed |
| WO-2019195384-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | TARVEDA THERAPEUTICS, INC. (US) | 2019-10-10 | — | — | WO | disclosed |
| US-20170296684-A1 | RADIOPHARMACEUTICAL CONJUGATE | UNIVERSITY OF CAPE TOWN (ZA) | 2017-10-19 | — | — | US | disclosed |
| US-20170296684-A1 | RADIOPHARMACEUTICAL CONJUGATE | UNIVERSITY OF CAPE TOWN (ZA) | 2017-10-19 | — | — | US | disclosed |
| US-9764048-B2 | Targeted molecular imaging probe and method for in vivo molecular imaging | SHEN BAOZHONG (CN) | 2017-09-19 | — | — | US | disclosed |
| WO-2016046793-A2 | RADIOPHARMACEUTICAL CONJUGATE | THE SOUTH AFRICAN NUCLEAR ENERGY CORPORATION LIMITED (ZA) | 2016-03-31 | — | — | WO | disclosed |
| US-20150202335-A1 | TARGETED MOLECULAR IMAGING PROBE AND METHOD FOR IN VIVO MOLECULAR IMAGING | SHEN BAOZHONG (CN) | 2015-07-23 | — | — | US | disclosed |
| EP-1898962-A1 | GASTRIN RELEASING PEPTIDE COMPOUNDS | Bracco Imaging, S.P.A. (IT) | 2008-03-19 | — | — | EP | disclosed |
| WO-2007002500-A1 | GASTRIN RELEASING PEPTIDE COMPOUNDS | BRACCO IMAGING S.P.A. (IT) | 2007-01-04 | — | — | WO | disclosed |
| WO-2004062574-A9 | IMPROVED LINKERS FOR RADIOPHARMACEUTICAL COMPOUNDS | BRACCO IMAGING SPA (IT) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10874753-B2 | Radiopharmaceutical conjugate of a metabolite and an EPR agent, for targeting tumour cells | EPRS1, FOLH1, SLC46A1 | SLC6A9 1357/4885HSD17B10 4082/4885ALB 2301/4885 |
| US-20230120220-A1 | PROCESS FOR SITE-SPECIFIC MODIFICATION OF AN ANTIBODY | OGA, GANAB, TGM1 | SLC6A9 1477/4885HSD17B10 4132/4885ALB 209/4885 |
| US-20150202335-A1 | TARGETED MOLECULAR IMAGING PROBE AND METHOD FOR IN VIVO MOLECULAR IMAGING | GJB2, GJA1, GAP43 | SLC6A9 3051/4885HSD17B10 3433/4885ALB 2293/4885 |
| US-20220184217-A1 | HSP90-BINDING CONJUGATES AND FORMULATIONS THEREOF | HSP90AB1, HSP90B1, HSP90AA1 | SLC6A9 2479/4885HSD17B10 1604/4885ALB 671/4885 |
| US-20170296684-A1 | RADIOPHARMACEUTICAL CONJUGATE | FOLH1, EPRS1, FOLR1 | SLC6A9 1573/4885HSD17B10 3900/4885ALB 2165/4885 |
| US-20210145971-A1 | HSP90-TARGETING CONJUGATES AND FORMULATIONS THEREOF | HSP90AB1, HSP90B1, HSP90AA1 | SLC6A9 2667/4885HSD17B10 1613/4885ALB 758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.